Invest2 distinct publishers3 min readPublished
Morgan Health led a Series E of more than $125m that values Thyme Care above $2bn, roughly double its mark from under a year ago. The payers on the cap table are underwriting a savings number the company validated itself.
The Investor · Invest desk
Compiled by The InvestorSomething wrong?How this is made
Buy versus build here turns on a denominator. Revenue passed $125m last year [6] against the more than $7bn of oncology spend the company says it manages [4], which is 1.8 cents of fee per dollar of claims moving through the model [1]. What that fee is meant to buy, on the company's own account, is a validated 5 to 10 percent reduction in total cost of care [5], or $350m to $700m on a $7bn base [2], which is 2.8 to 5.6 times the fee itself [3]. A payer staring at that ratio can build its own navigation network across all 50 states [4] and carry the fixed cost against one book of members, or it can write a check into infrastructure whose per-member cost falls every time another plan routes through it. Humana and CVS Health Ventures chose the second, alongside Morgan Health as lead [1] and, per the company, community oncology practices and health systems [14].
The price is the better puzzle, or rather the change in the price. More than $2bn on $125m of revenue is about 16 times [4]; the Series D, which CNBC reports was struck at roughly half that mark less than a year ago [3], implies something near $1bn on a revenue base of about $25m, if last year really was five times the prior one [6][5], and that is closer to 40 times [6]. Revenue grew fivefold and the valuation doubled [6][3]. For a business launched in 2020 [13], that is the trade a profitable company makes when it does not need the money.
And it does not. At more than $2bn post-money, $125m is under 6.3 percent of the equity [7], sold by a company that says it is profitable with positive free cash flow and a large balance sheet [7]. The allocation question is where it goes, and the answer is not deeper penetration of the 10.5 million people who can already reach the service [4]. It goes into Thyme Companies, a new parent entity that intends to spin up separate businesses in biosimilar adoption and clinical trial accrual, the first later this year [8], plus acquisitions and hiring [11]. Robin Shah, who stepped down as Thyme Care's chief executive in July [9] and now chairs the parent while Brad Diephuis runs the operating company [10], says there is no near-term view on an IPO [11].
This is probably wrong, but the reading I would defend is that the 5 to 10 percent is a multi-payer artifact, cheaper to rent at 1.8 percent of spend [1] than to reproduce inside one plan. There are a few ways that reading could give out. The savings figure is the company's, described as validated with no validator named [5], and if an independent count lands nearer 2 percent then the renewal talks and the $2bn move together. A sub-6-percent slug through a ventures arm [7] is ordinary portfolio behaviour rather than a sourcing decision, and the mark was set with institutional co-investors in the room [2]. And $7bn across 10.5 million lives is about $667 a head [8], which looks like the whole oncology claim line of a covered population rather than a managed subset, so "manages" is carrying weight the announcement never defines [4]. Of the two numbers this round is priced off, only the fee is one a payer can verify from its own claims file.
Ranked by verification strength, evidence, and original report placement.
Thyme Care announced on September 2, 2026 a Series E financing of over $125M at a valuation of more than $2B, led by Morgan Health with participation from strategic healthcare investors Humana and CVS Health Ventures.
Institutional investors in the round include AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.
CNBC reports the deal roughly doubled Thyme Care's valuation from a Series D less than a year ago.
Thyme Care services are available to more than 10.5 million people across all 50 states, and the company manages more than $7 billion in oncology spend.
Thyme Care's revenue surpassed $125 million last year, five times more than the previous year.
Shah said Thyme Care is now profitable, generating positive free cash flow, and has a large balance sheet to make investments it could not have made three years ago.
Distinct publishers with included, body-backed reporting in this cluster.
1 article · September 2, 2026
1 article · September 2, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
invest
A 6% cost cut, self-reported: Onos raises $17M with CVS Health Ventures on the cap table1 distinct publisher
invest
Beachwaver books about $2,000 of gross sales for every hour it stays on TikTok live1 distinct publisher
invest
Neno's 6.6M euro seed rests on one number: 200 clients per accountant1 distinct publisher
invest
Mamdani fills 15 council seats without a sitting executive from JPMorgan, BlackRock or Meta1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Two accounts, one supplier of facts
CNBC and the company's release read differently but draw on the same well. Every consequential figure — the $2bn mark, $7bn of managed spend, 10.5 million people, $125m of revenue, profitability — originates with Thyme Care or with Shah. Nothing in this reporting reflects an audit, a payer's own claims analysis or a document from the Series D, and the strongest outside voice is Morgan Health's CEO praising a company he just funded.
Real footprint, soft edges
Payers writing cheques is the hardest signal available: Humana and CVS Health Ventures now own equity in a company that bills them, and revenue that quintupled to $125m implies contracts someone renewed. The softer half is how reach is expressed — 10.5 million people 'have access', which is a covered-lives denominator rather than patients served, and $7bn is spend 'managed' rather than spend saved. No named health plan or health system customer appears anywhere in our coverage.
'Validated' is doing unpaid work
Take the savings claim at face value and Thyme Care is removing $350m to $700m a year from the system while collecting $125m for it — a 2.8-to-5.6x return that would be extraordinary if anyone outside the company had checked it. The word carrying that weight is 'validated', and it stands alone in the release with no study, plan or auditor behind it. CNBC's decision not to repeat the figure at all is its own quiet comment. The valuation, by contrast, is not obviously stretched for the sector; the gap is between the certainty of the language and the emptiness of the citation.
Everyone in frame is long the number
The release is the company's, distributed by a wire that does not check it. Morgan Health leads and its chief executive supplies the endorsing quote. Humana and CVS Health Ventures are simultaneously counterparties to and owners of a vendor whose savings claim only their data could refute, and the release's own framing leans on that payer breadth as proof of the model. CNBC, meanwhile, opens by noting Thyme Care sits at No. 18 on the Disruptor 50 — a ranking CNBC itself compiles.
Sound arithmetic, borrowed inputs
What can be computed here holds up — the multiple, the take rate, the prior-year base, the per-person spend all follow from figures both accounts agree on. What cannot be resolved is whether those figures are what the company says they are, and two specifics stay out of reach: the pre- or post-money basis of the valuation and the actual Series D mark. Confidence sits mid-range because the facts are consistent and consistently self-reported.